国际眼科杂志2026，Vol.26Issue(6)：931-939,9.DOI:10.3980/j.issn.1672－5123.2026.6.02
糖尿病视网膜病变的新型降糖药物研究进展
Advances in new hypoglycemic drugs for diabetic retinopathy
摘要
Abstract
•Diabetic retinopathy(DR)is a common complication in patients with diabetes mellitus(DM)that seriously affects the vision and quality of life.Ongoing research suggests that glucose － lowering therapies not only improve glycemic control but may also exert protective effects on DM related ocular complications.Although preliminary clinical data support this viewpoint,further in － depth exploration is warranted to investigate the specific mechanisms and efficacy of these drugs in DR.Currently,relevant research is still in the developmental stage and certain unresolved scientific questions and clinical challenges still exist.This narrative review summarizes the applications and recent advances of new hypoglycemic drugs in DR,with a focus on glucagon－like peptide－1 receptor agonists(GLP－1RA),sodium－glucose cotransporter － 2 inhibitors(SGLT2i),and dipeptidyl peptidase － 4 inhibitors(DPP － 4i),highlighting mechanistic evidence,available clinical findings,and future research directions to provide insights for DR management.关键词
糖尿病视网膜病变/新型降糖药物/胰高血糖素样肽－1受体激动剂/钠－葡萄糖协同转运蛋白2抑制剂/二肽基肽酶－4抑制剂Key words
diabetic retinopathy/new hypoglycemic drugs/glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter-2 inhibitors/dipeptidyl peptidase-4 inhibitors引用本文复制引用
杜佳荣,翟崧淇,于心茹,王春燕,王铭婕..糖尿病视网膜病变的新型降糖药物研究进展[J].国际眼科杂志,2026,26(6):931-939,9.基金项目
Specialized Regional Medical Center of Inner Mongolia Autonomous Region 内蒙古自治区专科区域医疗中心资助 （）
